Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1167

1.

Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users.

Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):93-9. doi: 10.1097/QAI.0b013e3181900129.

PMID:
19295339
2.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group.

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
3.

Crack cocaine use increases the incidence of AIDS-defining events in French Guiana.

Nacher M, Adenis A, Hanf M, Adriouch L, Vantilcke V, El Guedj M, Vaz T, Dufour J, Couppié P.

AIDS. 2009 Oct 23;23(16):2223-6. doi: 10.1097/QAD.0b013e32833147c2.

PMID:
19752716
4.

HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy.

Campa A, Yang Z, Lai S, Xue L, Phillips JC, Sales S, Page JB, Baum MK.

Clin Infect Dis. 2005 Oct 15;41(8):1179-85. Epub 2005 Aug 30.

PMID:
16163638
5.

Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.

Lucas GM, Cheever LW, Chaisson RE, Moore RD.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):251-9.

PMID:
11464144
6.

Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women.

Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL.

J Community Health. 2004 Apr;29(2):117-27.

PMID:
15065731
7.

Determinants of HIV progression and assessment of the optimal time to initiate highly active antiretroviral therapy: PISCIS Cohort (Spain).

Jaén A, Esteve A, Miró JM, Tural C, Montoliu A, Ferrer E, Riera M, Segura F, Force L, Sued O, Vilaró J, Garcia I, Masabeu A, Altès J, Coltet B, Podzamczer D, Murillas J, Navarro G, Gatell JM, Casabona J; PISCIS Study Group.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):212-20.

PMID:
18297762
8.

Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users.

Metsch LR, Pereyra M, Brewer TH.

J Subst Abuse. 2001;13(1-2):155-67.

PMID:
11547616
10.

Thrombocytopenia in HIV-infected drug users in the HAART era.

Burbano X, Miguez MJ, Lecusay R, Rodriguez A, Ruiz P, Morales G, Castillo G, Baum M, Shor-Posner G.

Platelets. 2001 Dec;12(8):456-61.

PMID:
11798394
11.

Risk of human immunodeficiency virus infection among pregnant crack cocaine users in a rural community.

Ellerbrock TV, Harrington PE, Bush TJ, Schoenfisch SA, Oxtoby MJ, Witte JJ.

Obstet Gynecol. 1995 Sep;86(3):400-4.

PMID:
7651651
12.

A prospective study of HIV disease progression in female and male drug users.

Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS.

AIDS. 1999 Feb 4;13(2):257-62.

PMID:
10202832
13.

Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy.

Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD.

Am J Epidemiol. 2006 Mar 1;163(5):412-20. Epub 2006 Jan 4.

PMID:
16394200
14.

Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study.

Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):221-5. doi: 10.1097/QAI.0b013e31815d2f59.

PMID:
18223361
15.

Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women.

Thorpe LE, Frederick M, Pitt J, Cheng I, Watts DH, Buschur S, Green K, Zorrilla C, Landesman SH, Hershow RC.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1423-30.

PMID:
15483472
16.

Alcohol use accelerates HIV disease progression.

Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A.

AIDS Res Hum Retroviruses. 2010 May;26(5):511-8. doi: 10.1089/aid.2009.0211.

17.

Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women.

Cook JA, Burke-Miller JK, Cohen MH, Cook RL, Vlahov D, Wilson TE, Golub ET, Schwartz RM, Howard AA, Ponath C, Plankey MW, Levine AM, Grey DD.

AIDS. 2008 Jul 11;22(11):1355-63. doi: 10.1097/QAD.0b013e32830507f2. Erratum in: AIDS. 2008 Sep 12;22(14):i. Levine, Andrea [corrected to Levine, Alexandra M].

18.

Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.

Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR.

J Infect Dis. 2007 Oct 1;196(7):1044-52. Epub 2007 Aug 29.

PMID:
17763327
19.

Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic.

Lucas GM, Gebo KA, Chaisson RE, Moore RD.

AIDS. 2002 Mar 29;16(5):767-74.

PMID:
11964533
20.

A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women.

Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, Stone VE, Smith DK, Schoenbaum EE; HER Study Group.

AIDS. 2002 Nov 8;16(16):2175-82.

PMID:
12409739

Supplemental Content

Support Center